MTOR and breast cancer: MLKL-mRNA treatment, combined with immune checkpoint blockade, has been proven to effectively enhance the anti-tumor activity.[25] The protein encoded by TSC1, associated with AC004076.2, impacts the regulation of mTOR activity and participates in the functional regulation of tumor-associated macrophages.[26] AC010168.2 was reported to modulate the protein-coding gene HIST4H4 to affect the survival of BC.[27] But in our study, AC010168.2 was associated with TRIM11.